Component
Human serum naringenin after conjugate hydrolysis
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.
Experimental context and source evidence
- dose
- 150, 300, 600 or 900 mg naringenin in whole-orange extract
- duration
- 24 hours with at least one-week washout
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Eighteen healthy adults in a randomized crossover trial
- limitations
- The assay reported total released aglycone after hydrolysis and does not equal free circulating naringenin; this was a single-dose safety/PK trial.
- nutrient_topic
- Naringenin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Naringenin
- organism
- Eighteen healthy adults in a randomized crossover trial
- plain_language
- Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses.
- primary_references
- Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31468636/ DOI: 10.1111/dom.13868
- route
- Oral
- tissue
- Serum LC-MS after beta-glucuronidase/sulfatase hydrolysis
Naringenin: mechanism of action and interactions (2026-09-20) · lines 11–20
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Eighteen healthy adults in a randomized crossover trial · source_derived_draft · unverified_draft
## naringenin-human-pk Whole-orange extract supplying 150-900 mg naringenin produced dose-related serum exposure in 18 adults; half-life was about 2.65-3.0 hours at the fully profiled doses. Model/species: Eighteen healthy adults in a randomized crossover trial Tissue/system: Serum LC-MS after beta-glucuronidase/sulfatase hydrolysis Exposure: 150, 300, 600 or 900 mg naringenin in whole-orange extract Route: Oral Duration: 24 hours with at least one-week washout Limits: The assay reported total released aglycone after hydrolysis and does not equal free circulating naringenin; this was a single-dose safety/PK trial. Primary reference: Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31468636/ DOI: 10.1111/dom.13868 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.